McKesson Corporation with ticker code (MCK) have now 14 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 450 and 320 with a mean TP of 409.43. Now with the previous closing price of 377.73 this is indicating there is a potential upside of 8.4%. There is a 50 day moving average of 363.4 and the 200 moving average now moves to 331.67. The company has a market capitalisation of $53,988m. Find out more information at: https://www.mckesson.com
The potential market cap would be $58,518m based on the market concensus.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
